254 related articles for article (PubMed ID: 30580911)
1. [Donor Lymphocyte Infusions (DLI): Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
De Vos J; Baudoux E; Bay JO; Calmels B; Cras A; El Cheikh J; Guerout-Verite MA; Lacassagne MN; Lamure S; Letellier C; Menard AL; Daguindau E; Poiré X; Yakoub-Agha I; Guillaume T
Bull Cancer; 2019 Jan; 106(1S):S35-S39. PubMed ID: 30580911
[TBL] [Abstract][Full Text] [Related]
2. [Preventative and therapeutic relapse strategies after allogeneic hematopoietic stem cell transplantation: Guidelines from the Francophone society of bone marrow transplantation and cellular therapy (SFGM-TC)].
Yafour N; Beckerich F; Bulabois CE; Chevallier P; Daguindau É; Dumesnil C; Guillaume T; Huynh A; Levrat SM; Menard AL; Michallet M; Pautas C; Poiré X; Ravinet A; Yakoub-Agha I; Bazarbachi A
Bull Cancer; 2017 Dec; 104(12S):S84-S98. PubMed ID: 29179894
[TBL] [Abstract][Full Text] [Related]
3. [Prophylactic, preemptive and curative use of donor lymphocyte infusion in patients undergoing allogeneic stem cell transplantation: guidelines of the SFGM-TC].
Guillaume T; Porcheron S; Audat F; Bancillon N; Berceanu A; Charbonnier A; Dulery R; Edy N; El Cheikh J; Hermet E; Maurer N; Paul F; Konopacki-Potet J; Turlure P; Wallart A; Boulanger F; Dhédin N; Suarez F; Yakoub-Agha I;
Pathol Biol (Paris); 2014 Aug; 62(4):193-6. PubMed ID: 24996843
[TBL] [Abstract][Full Text] [Related]
4. Unrelated donor leukocyte infusions to treat relapse after unrelated donor bone marrow transplantation.
Leis J; Porter DL
Leuk Lymphoma; 2002 Jan; 43(1):9-17. PubMed ID: 11908741
[TBL] [Abstract][Full Text] [Related]
5. Individually adjusted prophylactic donor lymphocyte infusions after CD34-selected allogeneic peripheral blood stem cell transplantation.
Ferrá C; Rodríguez-Luaces M; Gallardo D; Encuentra M; Martín-Henao GA; Peris J; Ancín I; Sarrá J; Berlanga JJ; García J; Grañena A
Bone Marrow Transplant; 2001 Nov; 28(10):963-8. PubMed ID: 11753552
[TBL] [Abstract][Full Text] [Related]
6. Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation.
Luznik L; Fuchs EJ
Cancer Control; 2002; 9(2):123-37. PubMed ID: 11965233
[TBL] [Abstract][Full Text] [Related]
7. Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?
Radujkovic A; Guglielmi C; Bergantini S; Iacobelli S; van Biezen A; Milojkovic D; Gratwohl A; Schattenberg AV; Verdonck LF; Niederwieser DW; de Witte T; Kröger N; Olavarria E;
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1230-6. PubMed ID: 25797175
[TBL] [Abstract][Full Text] [Related]
8. [Haploidentical hematopoietic stem cell transplantation: Guidelines from the Francophone society of marrow transplantation and cellular therapy (SFGM-TC)].
Nguyen S; Chalandon Y; Lemarie C; Simon S; Masson D; Dhedin N; Suarez F; Renaud B; Charbonnier A; Yafour N; François S; Duléry R; Blaise D; Yakoub-Agha I; Rubio MT
Bull Cancer; 2016 Nov; 103(11S):S229-S242. PubMed ID: 27842860
[TBL] [Abstract][Full Text] [Related]
9. Low-dose methotrexate may preserve a stronger antileukemic effect than that of cyclosporine after modified donor lymphocyte infusion in unmanipulated haploidentical HSCT.
Yan CH; Xu LP; Liu DH; Chen H; Wang Y; Wang JZ; Wang FR; Han W; Liu KY; Huang XJ
Clin Transplant; 2015 Jul; 29(7):594-605. PubMed ID: 25969866
[TBL] [Abstract][Full Text] [Related]
10. A retrospective single-center analysis of G-CSF-mobilized donor lymphocyte infusion in hematologic malignancies after unmanipulated allogenic PBSCT.
Lu N; Lin J; Wang LL; Li YY; Wang LJ; Gao CJ; Liu DH; Gao XN
Int J Hematol; 2022 May; 115(5):713-727. PubMed ID: 35128587
[TBL] [Abstract][Full Text] [Related]
11. Donor lymphocyte infusions for relapse after allogeneic transplantation: when, if and for whom?
Chang YJ; Huang XJ
Blood Rev; 2013 Jan; 27(1):55-62. PubMed ID: 23261066
[TBL] [Abstract][Full Text] [Related]
12. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
Collins RH; Shpilberg O; Drobyski WR; Porter DL; Giralt S; Champlin R; Goodman SA; Wolff SN; Hu W; Verfaillie C; List A; Dalton W; Ognoskie N; Chetrit A; Antin JH; Nemunaitis J
J Clin Oncol; 1997 Feb; 15(2):433-44. PubMed ID: 9053463
[TBL] [Abstract][Full Text] [Related]
13. Treatment of relapse after allogeneic bone marrow transplantation with unmanipulated G-CSF-mobilized peripheral blood stem cell preparation.
Siegert W; Beyer J; Kingreen D; Blasczyk R; Baurmann H; Schwella N; Schleicher J; Kirsch A; Huhn D
Bone Marrow Transplant; 1998 Sep; 22(6):579-83. PubMed ID: 9758347
[TBL] [Abstract][Full Text] [Related]
14. [Management of graft failure and erythroblastopenia in patients undergoing allogeneic hematopoietic stem cell transplantation: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Cornillon J; Sicre de Fontbrune F; Chantepie S; Coiteux V; Gauthier J; Masouridi-Levrat S; Pochon C; Terriou L; Yakoub-Agha I; Dalle JH
Bull Cancer; 2016 Nov; 103(11S):S248-S254. PubMed ID: 27810141
[TBL] [Abstract][Full Text] [Related]
15. [Secondary cancers following allogeneic hematopoietic stem cell transplantation: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Loschi M; Alsuliman T; Cabrera Q; Desbrosses Y; Desmier D; Yakoub Agha I; Guillaume T
Bull Cancer; 2024 Feb; 111(2S):S22-S28. PubMed ID: 36922321
[TBL] [Abstract][Full Text] [Related]
16. Invariant NKT Cells From Donor Lymphocyte Infusions (DLI-iNKTs) Promote
Jahnke S; Schmid H; Secker KA; Einhaus J; Duerr-Stoerzer S; Keppeler H; Schober-Melms I; Baur R; Schumm M; Handgretinger R; Bethge W; Kanz L; Schneidawind C; Schneidawind D
Front Immunol; 2019; 10():1542. PubMed ID: 31354710
[TBL] [Abstract][Full Text] [Related]
17. Pilot study of prophylactic ex vivo costimulated donor leukocyte infusion after reduced-intensity conditioned allogeneic stem cell transplantation.
Kumar AJ; Hexner EO; Frey NV; Luger SM; Loren AW; Reshef R; Boyer J; Smith J; Stadtmauer EA; Levine BL; June CH; Porter DL; Goldstein SC
Biol Blood Marrow Transplant; 2013 Jul; 19(7):1094-101. PubMed ID: 23635453
[TBL] [Abstract][Full Text] [Related]
18. Graft-versus-leukemia effect with a WT1-specific T-cell response induced by azacitidine and donor lymphocyte infusions after allogeneic hematopoietic stem cell transplantation.
Ishikawa T; Fujii N; Imada M; Aoe M; Meguri Y; Inomata T; Nakashima H; Fujii K; Yoshida S; Nishimori H; Matsuoka KI; Kondo E; Maeda Y; Tanimoto M
Cytotherapy; 2017 Apr; 19(4):514-520. PubMed ID: 28139337
[TBL] [Abstract][Full Text] [Related]
19. Modified donor lymphocyte infusion-associated acute graft-versus-host disease after haploidentical T-cell-replete hematopoietic stem cell transplantation: incidence and risk factors.
Yan CH; Liu DH; Xu LP; Liu KY; Zhao T; Wang Y; Chen H; Chen YH; Han W; Huang XJ
Clin Transplant; 2012; 26(6):868-76. PubMed ID: 22432715
[TBL] [Abstract][Full Text] [Related]
20. Pre-emptive immunotherapy with CD8-depleted donor lymphocytes after CD34-selected allogeneic peripheral blood stem cell transplantation.
Baron F; Siquet J; Schaaf-Lafontaine N; Baudoux E; Hermanne JP; Fillet G; Beguin Y
Haematologica; 2002 Jan; 87(1):78-88. PubMed ID: 11801468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
